Knowing Your Values
Does a medicine’s price consistently track with its benefits and value? Not in the US, according to a study
Stephanie Sutton |
Many healthcare authorities place a strong emphasis on value when it comes to deciding which medicines to include in national health programs. Decisions are strongly driven by health technology assessment agencies who closely scrutinize the price and expected health benefits of a new medicine. In other countries, it’s more of a blackbox approach. The US appears to fall into the latter category.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.